16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impact of leaflet thrombosis on hemodynamics and clinical outcomes after bioprosthetic aortic valve replacement: A meta‐analysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Leaflet thrombosis (LT, also called cusp thrombosis) detected by multidetector computed tomography (MDCT) is common in bioprosthetic aortic valve replacement (bAVR). However, it remains contradictory whether MDCT‐defined LT following bAVR is associated with hemodynamic deterioration and stroke. Thus, we performed the first meta‐analysis to assess hemodynamic outcomes and updated the latest researches on the clinical outcomes of MDCT‐defined LT after bAVR.

          Hypothesis

          MDCT‐defined LT might be associated with worse hemodynamic and clinical outcomes after bAVR.

          Method

          MEDLINE, EMBASE, Cochrane Library, and http://clinicaltrial.gov were searched from inception to 15th April 2019. The fix‐effect model was utilized to calculate odds ratio (OR) and 95% confidence interval (CI). The primary outcomes were hemodynamic stability indexes, including mean pressure gradient (MPG), left ventricular ejection fraction (LVEF), paravalvular leak (PVL), and clinical heart failure. The secondary endpoints were major adverse cardiovascular and cerebrovascular events (MACCEs), which consisted of myocardial infarction, all‐cause death, stroke, and transient ischemic attack (TIA).

          Results

          Twelve studies with 4820 patients were included. The total prevalence of MDCT‐defined LT was 9.7%. MDCT‐defined LT was associated with a significantly increased risk of MPG (inverse variance 0.43, 95% CI: [0.30, 0.57]), MACCEs (OR 2.43, 95% CI: [1.45, 4.06]), stroke (OR 1.79, 95% CI: [1.03, 3.11]), and TIA (OR 4.09, 95% CI: [1.59, 10.54]). There were no differences for other outcomes.

          Conclusions

          MDCT‐defined LT after bAVR is associated with increased MPG and increased risk of adverse cerebrovascular events, including TIA and stroke. While LVEF, PVL, and clinical heart failure were similar between patient with and without LT.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study.

          Subclinical leaflet thrombosis of bioprosthetic aortic valves after transcatheter valve replacement (TAVR) and surgical aortic valve replacement (SAVR) has been found with CT imaging. The objective of this study was to report the prevalence of subclinical leaflet thrombosis in surgical and transcatheter aortic valves and the effect of novel oral anticoagulants (NOACs) on the subclinical leaflet thrombosis and subsequent valve haemodynamics and clinical outcomes on the basis of two registries of patients who had CT imaging done after TAVR or SAVR.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves

            A finding of reduced aortic-valve leaflet motion was noted on computed tomography (CT) in a patient who had a stroke after transcatheter aortic-valve replacement (TAVR) during an ongoing clinical trial. This finding raised a concern about possible subclinical leaflet thrombosis and prompted further investigation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration

              Cardiac thromboembolism attributed to atrial fibrillation (AF) is responsible for up to one-third of ischemic strokes. Stroke may be the first manifestation of previously undetected AF. Given the efficacy of oral anticoagulants in preventing AF-related ischemic strokes, strategies of searching for AF after a stroke using ECG monitoring followed by oral anticoagulation (OAC) treatment have been proposed to prevent recurrent cardioembolic strokes. This white paper by experts from the AF-SCREEN International Collaboration summarizes existing evidence and knowledge gaps on searching for AF after a stroke by using ECG monitoring. New AF can be detected by routine plus intensive ECG monitoring in approximately one-quarter of patients with ischemic stroke. It may be causal, a bystander, or neurogenically induced by the stroke. AF after a stroke is a risk factor for thromboembolism and a strong marker for atrial myopathy. After acute ischemic stroke, patients should undergo 72 hours of electrocardiographic monitoring to detect AF. The diagnosis requires an ECG of sufficient quality for confirmation by a health professional with ECG rhythm expertise. AF detection rate is a function of monitoring duration and quality of analysis, AF episode definition, interval from stroke to monitoring commencement, and patient characteristics including old age, certain ECG alterations, and stroke type. Markers of atrial myopathy (eg, imaging, atrial ectopy, natriuretic peptides) may increase AF yield from monitoring and could be used to guide patient selection for more intensive/prolonged poststroke ECG monitoring. Atrial myopathy without detected AF is not currently sufficient to initiate OAC. The concept of embolic stroke of unknown source is not proven to identify patients who have had a stroke benefitting from empiric OAC treatment. However, some embolic stroke of unknown source subgroups (eg, advanced age, atrial enlargement) might benefit more from non–vitamin K-dependent OAC therapy than aspirin. Fulfilling embolic stroke of unknown source criteria is an indication neither for empiric non–vitamin K-dependent OAC treatment nor for withholding prolonged ECG monitoring for AF. Clinically diagnosed AF after a stroke or a transient ischemic attack is associated with significantly increased risk of recurrent stroke or systemic embolism, in particular, with additional stroke risk factors, and requires OAC rather than antiplatelet therapy. The minimum subclinical AF duration required on ECG monitoring poststroke/transient ischemic attack to recommend OAC therapy is debated.
                Bookmark

                Author and article information

                Contributors
                masm@sj-hospital.org
                Journal
                Clin Cardiol
                Clin Cardiol
                10.1002/(ISSN)1932-8737
                CLC
                Clinical Cardiology
                Wiley Periodicals, Inc. (New York )
                0160-9289
                1932-8737
                20 January 2020
                May 2020
                : 43
                : 5 ( doiID: 10.1002/clc.v43.5 )
                : 468-474
                Affiliations
                [ 1 ] Department of Cardiology Shengjing Hospital of China Medical University Shengyang Liaoning Province People's Republic of China
                Author notes
                [*] [* ] Correspondence

                Shumei Ma, MD, PhD, Department of Cardiology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang 110004, Liaoning Province, People's Republic of China.

                Email: masm@ 123456sj-hospital.org

                Author information
                https://orcid.org/0000-0001-5546-0029
                Article
                CLC23331
                10.1002/clc.23331
                7244303
                31957895
                4e70dd6f-b001-4768-9cee-ad43a07b7389
                © 2020 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 11 October 2019
                : 05 December 2019
                : 02 January 2020
                Page count
                Figures: 4, Tables: 1, Pages: 7, Words: 5326
                Categories
                Clinical Investigations
                Clinical Investigations
                Custom metadata
                2.0
                May 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.2 mode:remove_FC converted:22.05.2020

                Cardiovascular Medicine
                aortic stenosis,bioprosthetic aortic valve,surgical aortic valve replacement,thrombosis,transcatheter aortic valve replacement

                Comments

                Comment on this article